JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andela, V B
Right arrow Articles by Rosier, R N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andela, V B
Right arrow Articles by Rosier, R N
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Bone Cancer
Journal of Clinical Pathology 2005;58:328-330
© 2005 BMJ Publishing Group Ltd & Association of Clinical Pathologists


SHORT REPORT

An immunohistochemical analysis to evaluate an inverse correlation between Runx2/Cbfa1 and NF{kappa}B in human osteosarcoma

V B Andela1, F Siddiqui2, A Groman3, R N Rosier2

1 The James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue Box 665, Rochester, NY, 14642, USA
2 The Department of Orthopaedics, Center for Musculoskeletal Research, University of Rochester Medical Center
3 The Department of Biostatistics, University of Rochester Medical Center

Correspondence to:
Dr V B Andela
University of Rochester Medical Center, 601 Elmwood Avenue Box 665, Rochester, NY, 14642, USA; v_andela{at}yahoo.com
ABSTRACT
Background: Dominant negative inhibition of nuclear factor {kappa}B (NF{kappa}B) signalling activity in a human osteosarcoma cell line (Saos2) results in malignant reversion and the induction of the osteoblast differentiating transcription factor, Runx2/Cbfa1. This observation suggests that there is an inverse relation between a transcription factor associated with malignant progression and chemoresistance (NF{kappa}B) and an osteoblast differentiating transcription factor (Runx2/Cbfa1).

Aims: To assess and correlate Runx2/Cbfa1 and NF{kappa}B (p65) immunoreactivity in human osteosarcoma.

Methods: Runx2/Cbfa1 and NF{kappa}B (p65) immunoreactivity was assessed on 11 paraffin wax embedded archival specimens of human primary osteosarcoma by standard immunohistochemical methods and scored on a scale of 0–3. A Pearson correlation analysis between Runx2/Cbfa1 and NF{kappa}B (p65) scores was established.

Results: Runx2/Cbfa1 was expressed constitutively in all pathology specimens of human osteosarcoma. Of note, a chondroblastic osteosarcoma showed the highest Runx2/Cbfa1 immunoreactivity. A Pearson correlation did not support an inverse correlation between Runx2/Cbfa1 and NF{kappa}B (p65) scores (r = 0.57) in human osteosarcoma.

Conclusion: Runx2/Cbfa1 immunoreactivity does not inversely correlate with NF{kappa}B immunoreactivity, and thus cannot serve as an indirect measure of NF{kappa}B activity or an independent predictive or prognostic indicator.


Abbreviations: NF{kappa}B, nuclear factor {kappa}B; Rb, retinoblastoma protein

Keywords: differentiation; nuclear factor {kappa}B; osteosarcoma; Runx2/Cbfa1; transformation







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.